Bahadur, Gulam;
Homburg, Roy;
Muneer, Asif;
Racich, Paul;
Jayaprakasan, Kanna;
Acharya, Santanu;
Jauniaux, Eric;
(2022)
Global inequality in sub-fertility treatment needs safer, cost effective, evidence-based and economically viable choices for patients and stakeholders.
JBRA Assisted Reproduction
, 26
(1)
pp. 1-2.
10.5935/1518-0557.20210111.
Preview |
Text
Global inequality in sub-fertility treatment needs safer, cost effective, evidence-based and economically viable choices for.pdf - Published Version Download (116kB) | Preview |
Abstract
The global increase in subfertility diagnosis and treatments and the rise of private equity investors concentrating on high profits based on in vitro fertilisation (IVF) treatments raise profound societal and economic questions for stakeholders and patients. The question remains as to whose benefits will ultimately be greater when promoting high margins treatment options resulting from cross-border mergers and acquisitions of IVF clinics.This paper covers wide-ranging issues from the erroneously constructed UK National Institute for Health and Care Excellence's (NICE) guidelines on treatment choices, the cost-effectiveness of treatments, the promotion of IVF, and add-ons where evidence remains minimal, the commercial size of the fertility industry. Investment in improving intrauterine insemination (IUI) success rates has understandably been avoided for its short-term impact on the IVF industry. However, IUI efficiency would cut across many of the global subfertility treatment economic and access problems while allowing stakeholder, feepaying, and patients financial savings will likely allow for more funded IVF cycles in acutely deserving cases. The recommendations will help expand choices for globally economically challenged patients' and services while enhancing an ethical and moral dimension towards fertility treatment choices for patients and stakeholders.
Archive Staff Only
 |
View Item |
